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Abstract
Diffuse large B- cell lymphoma (DLBCL) is the most common form of non- 
Hodgkin’s lymphoma. R- CHOP is currently the standard therapy for DLBCL, 
but the prognosis of refractory or recurrent patients remains poor. In this study, 
we synthesized a new water- soluble antimalarial drug artemisinin derivative, 
SM1044. The treatment of DLBCL cell lines with SM1044 induces autophagy- 
dependent apoptosis, which is directed by an accelerated degradation of the 
antiapoptosis protein Survivin, via its acetylation- dependent interaction with 
the autophagy- related protein LC3- II. Additionally, SM1044 also stimulates the 
de novo synthesis of ceramide, which in turn activates the CaMKK2–AMPK–
ULK1 axis, leading to the initiation of autophagy. Our findings not only elucidate 
the mechanism of autophagy- dependent apoptosis in DLBCL cells, but also 
suggest that SM1044 is a promising therapeutic molecule for the treatment of 
DLBCL, along with R- CHOP regimen.
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Introduction
Diffuse large B- cell lymphoma (DLBCL) is a common 
aggressive malignancy of mature B cells, accounting for 
30–40% of adult non- Hodgkin’s lymphoma (NHL). 
R- CHOP (rituximab and CHOP regimen) is currently the 
most approved standard of care for DLBCL, which sig-
nificantly improved the therapeutic effects and prognosis 
of patients. Unfortunately, approximately 10–15% of cases 
are refractory to the treatment, and 20–30% of responders 
relapse [1]. Even worse, roughly 50% of the relapsed cases 
are not eligible for high- dose chemotherapy with a sub-
sequent autologous stem cell transplantation (ASCT) [2]. 
Thus, the prognosis of patients with relapsed or refractory 
DLBCL is still poor. International prognostic index (IPI) 
has long been established as the main prognostic indicator 
for aggressive NHL, including DLBCL. However, IPI only 
includes clinical parameters, and not biological indicators. 
Accumulating evidence suggests that molecular markers, 
such as high expression of Survivin, could be associated 
with poor prognosis DLBCL cases [3, 4].
Survivin is the smallest member of the inhibitors of 
apoptosis protein (IAPs) family, highly conserved during 
evolution, and is involved in the regulation of both cell 
division and apoptosis. Survivin has increasingly been rec-
ognized as a tumor gene because it is rarely expressed in 
normal differentiated tissues, while highly expressed in 
various cancers and mostly correlated with inferior out-
comes [5, 6]. Positive Survivin has also been closely related 
to tumor progression and chemoresistance [5, 7]. In DLBCL, 
Survivin is overexpressed in up to 60% of the cases, and 
is associated with advanced clinical stage, reduced remis-
sion rate, shortened event- free survival, as well as increased 
chemoresistance and relapse [8, 9]. In addition, Survivin- 
positive DLBCL patients seem to benefit less from R- CHOP 
regimen compared to Survivin- negative cases [4].
Interestingly, the knockdown of Survivin leads to sig-
nificant apoptosis and growth inhibition of DLBCL cell 
lines, while its overexpression protects the cells from death 
[10, 11]. In recent years, great efforts have been employed 
to test the feasibility and effectiveness of Survivin inhibi-
tion in treating tumors [12, 13]. Currently, the selective 
Survivin inhibitor YM155 has been well validated in vitro 
and in vivo, and several clinical trials are ongoing to test 
its efficacy in patients [14–16]. Thus, the downregulation 
or suppression of Survivin could be an attractive strategy 
for the treatment of DLBCL.
Artemisinin (ART) is one of the most potent and effective 
antimalarial molecules, first isolated from Artemisia annua 
L. in 1972 by Youyou Tu, who won the Nobel Prize in 
2015. Since 1992, increasing number of studies have found 
that ART and its derivatives, such as dihydroartemisinin 
(DHA), artemether (ARM), and artesunate (ARS) have potent 
antitumor activities [17–20]. However, most of the ART 
derivatives, including ART itself, are insoluble or unstable in 
water, which significantly decreases the bioavailability of these 
drugs [21, 22]. In order to overcome this shortcoming of 
ARTs, our group, together with Shanghai Institute of Materia 
Medica, brought specific structural modifications to ART and 
its derivatives. Among these modified products, SM1044, a 
new synthesized ART maleate, exhibited excellent water solu-
bility, and the aqueous solution was quite stable.
Autophagy is an evolutionarily conserved process that 
degrades and eliminates the unwanted or dysfunctional intra-
cellular components, such as misfolded proteins and organelles. 
Initiated by activation of the ULK1 complex, a double- 
membrane vesicle called autophagosome is formed, which 
subsequently fuses with the lysosome, forming the autolyso-
some, whose inner contents are degraded and recycled. A 
number of autophagy- related genes (ATGs) are involved in 
the regulation of autophagy, among which LC3/ATG8 plays 
a key role in the membrane formation of both the autophago-
some and autolysosome [23]. In most cases, autophagy protects 
cells from death under adverse conditions. Paradoxically, 
autophagy may also trigger cell death, including apoptosis 
[24–27]. However, the mechanism of autophagy- dependent 
apoptosis has not yet been well elucidated.
In the present study, we observe a remarkable antitumor 
effect of SM1044 on several DLBCL cell lines and explore 
the possible mechanisms underlying the activity of SM1044. 
In short, we demonstrate that SM1044 treatment affects 
DLBCL cell survival both in vitro and in vivo, through 
the induction of autophagy as well as an autophagy- 
dependent degradation of Survivin, followed by caspase- 
dependent apoptosis.
Materials and Methods
Cell culture
DLBCL cell lines SU- DHL- 4, SU- DHL- 10, and OCI- LY3 
were obtained from the French National Institute of 
Health and Medical Research (INSERM). SU- DHL- 4 was 
cultured in RPMI 1640 medium (Gibco, Carlsbad, CA) 
supplemented with 10% fetal bovine serum (FBS, Moregate 
Biotech, Bulimba, QLD, Australia). SU- DHL- 10 was cul-
tured in RPMI 1640 medium supplemented with 20% 
FBS. OCI- LY3 was cultured in Iscove’s modified Dulbecco’s 
medium (Gibco) supplemented with 20% FBS. All three 
cell lines were cultured at 37°C in a 5% CO2 atmosphere. 
Authentication of cell line was performed and the profile 
was compared with that in DSMZ STR database.
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Reagents and antibodies
SM1044 was synthesized by Shanghai Institute of Materia Medica, 
Chinese Academy of Sciences, and dissolved in sterile purified 
water. ART, DHA, ARM, and ARS were generous gifts from 
Chongqing Huali Wulingshan Medicine company. Z- VAD- FMK 
and enhanced ATP assay kit were purchased from Beyotime 
Biotechnology (Haimen, Jiangsu, China). Chloroquine and 
bafilomycin A1 (Baf A1) were purchased from Sigma- Aldrich 
(St. Louis, MO). MG132, STO- 609, l- cycloserine, and cyclohex-
imide (CHX) were purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA). C646 and Compound C were purchased 
from Selleck Chemicals (Houston, TX). Sphingosine- 1- phosphate 
(S1P) was obtained from LKT Laboratories (St. Paul, MN). 
Antibodies against caspase- 3, caspase- 8, caspase- 9, PARP, 
Survivin, XIAP, Flip, Bcl- xL, Bcl- w, A1/Bfl- 1, LC3, p- AMPK, 
p- mTOR, p- ULK1, and p- LKB1 were purchased from Cell 
Signaling Technology (CST, Danvers, MA); anti- Bcl- 2, P300/
CBP, and Mcl- 1 were purchased from Santa Cruz Biotechnology; 
β- actin was purchased from Sigma- Aldrich.
Cell viability assay
Cell viability was determined by Cell Counting Kit- 8 
(CCK8, Dojindo Laboratories, Kumamoto, Japan) accord-
ing to the manufacturer’s instructions. The percent inhibi-
tion was calculated using the following formula: Percent 
inhibition = [(Mean absorbance of the control 
well − Mean absorbance of the test well)/(Mean absorb-
ance of the control well − Mean absorbance of the blank 
well)] × 100%.
Apoptosis assessment by Annexin V staining
Cells were washed with 1× PBS buffer followed by 1× 
Annexin V buffer and resuspended in 200 μL staining 
solution comprising 2 μL fluorescein isothiocyanate- 
Annexin V and 2 μL propidiumiodide (PI) (FITC- Annexin 
V staining kit, BD Biosciences, San Jose, CA). Then, 
1 × 104 cells were measured by flow cytometry. All data 
were collected and analyzed by the FlowJo software (FlowJo 
LLC, Ashland, Oregon, USA).
Protein extraction, coimmunoprecipitation 
(co- IP), and western blot analysis
Protein extraction, co- IP, and western blot analysis were 
carried out as described previously [28].
Transmission electron microscopy
SU- DHL- 4 cells were fixed in 0.1 mol/L sodium cacodylate 
buffer (pH 7.3) containing 2% paraformaldehyde and 2.5% 
glutaraldehyde and embedded in resin mixture of Embed 
812 and araldite. The samples were then dissected into 
70- nm- thick slices and poststained with 3% uranyl acetate 
and Reynolds lead citrate. Finally, the samples were exam-
ined under FEI Tecnai Spirit G2 TEM and digital images 
were captured by an FEI Eagle camera.
RNA extraction and real- time PCR
Total RNA was extracted using Trizol reagent (Invitrogen, 
Carlsbad, CA) and the cDNA was obtained using an 
M- MLV reverse transcriptase (Invitrogen). Real- time quan-
titative polymerase chain reaction PCR (real- time PCR) 
assay was performed using SuperReal PreMix Plus kit 
(Tiangen, Beijing, China). The primers were as follows: 
GAPDH (forward: GAAGGTGAAGGTCGGAGTC, reverse: 
GAAGATGGTGATGGGATTTC); Survivin (forward: 
TTTCTCAAGGACCACCGCATCTC, reverse: GCTCGTTC 
TCAGTGGGGCAGTG). Amplifications were performed in 
a 7500 Real- Time PCR System (Applied Biosystems, Foster 
City, CA).
Electroporation
Cells were centrifuged at 90g for 10 min, the superna-
tants were removed, the cell pellets were resuspended 
in 4D- Nucleofector™ solution (SF cell line 
4D- Nucleofector X kit L, Lonza, Basel, Switzerland) con-
taining the plasmids and transferred into the 
Nucleocuvette™ vessels. The vessels were then placed into 
the retainer of the 4D- Nucleofector™ X unit and the 
Nucleofection™ process was ran with program DN- 100. 
After the run completed, the vessels were removed from 
the retainer and incubated for 10 min. The cells were 
resuspended with prewarmed medium and mixed by 
pipetting for three times, then plated onto cell culture 
plates for further experiments.
Construction of lentiviral expression vectors
pLVX- shRNA2 vector was obtained from Clontech 
Laboratories (Mountain View, CA). Recombinant lentiviral 
shLC3 (with a target sequence 5′- CTGAGATCGATCA 
GTTCAT- 3′) was constructed according to the manufac-
turer’s instructions. The pLVX- IRES- Puro vector was also 
obtained from Clontech Laboratories. The cDNA of 
Survivin was amplified by PCR and cloned into pLVX- 
IRES- Puro vector. The extended LC3- interacting region 
(xLIR) motif mutated Survivin (forward primer: 5′- GGT
GAATTTTTGAAAGGGGACAGAGAA- 3′, reverse primer: 
5′- CCTTTCAAAAATTCACCAAGGGTTAAT- 3′) was con-
structed using a Fast Mutagenesis System (TransGen 
Biotechnology, Beijing, China).
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Enhanced ATP assay
The level of intracellular ATP was determined using an 
enhanced ATP assay kit (Beyotime Biotechnology) accord-
ing to the manufacturer’s instructions. Briefly, equal 
amounts of cells were harvested, lysed, and centrifuged at 
12,000g for 5 min at 4°C. Then, 20 μL of the supernatant 
was mixed with 100 μL of luciferase reagent and the meas-
urements were done using a microplate luminometer.
Measurement of ceramide
Cell pellets were resuspended with 200 μL 1× PBS, vor-
texed, and sonicated for 30 min. Then, 1.8 mL extraction 
solvent A (isopropanol/ethyl acetate, 1:2, v/v) was added, 
vortexed, and sonicated for another 30 min. After cen-
trifugation at 2000g for 10 min, the supernatant was col-
lected. Next, 2 mL extraction solvent B (isopropanol/ethyl 
acetate/H2O, 3:6:1, v/v/v) was added into the residue, 
vortexed, and sonicated for 30 min. After centrifugation, 
the supernatant was collected and mixed with the previ-
ous one. Then, the extraction was evaporated to dryness 
under nitrogen. The dried residue was dissolved in 500 μL 
methanol, followed by filtration through a 0.45- μm PVDF 
membrane. Finally, 2 μL solution was injected into a 
HPLC- MS/MS system for test.
In vivo xenograft model
Female nude mice (4- to 6- week- old) were housed and 
monitored at the Department of Laboratory Animal Science, 
Shanghai Jiao Tong University School of Medicine. All 
animal experiments were approved by the Institutional 
Review Board of Shanghai Jiao Tong University School 
of Medicine, and complied with the ARRIVE guidelines. 
Nude mice were subcutaneously inoculated in the right 
flank with 1.5 × 107 SU- DHL- 4 cells suspended in 100 μL 
1× PBS. The two largest perpendicular axes were measured 
with standard calipers, and tumor volume was calculated 
using the following formula: (length) × (width)2/2 as 
previously reported [28]. When tumors reached 5 mm 
in the length, mice were randomly separated into vehicle 
control (normal saline, n = 11) or SM1044 (5 mg/kg per 
day, n = 12) treatment groups. Tumor size and body 
weight were measured, and mice were photographed every 
2 days. Animals were euthanized when tumors reached 
15 mm in the length.
Statistical analyses
The data are expressed as the mean ± SEM. The signifi-
cance was calculated using Student’s t- test. A value of 
P < 0.05 was considered to be significant.
Results
Treatment of DLBCL cell lines with SM1044 
inhibits cell growth and induces apoptosis
First, we evaluated the effects of a SM1044 (Fig. 1A) 
treatment on cell survival in several lymphoma cell lines 
and found that SM1044 severely affected cell viability, 
especially in SU- DHL- 4, a typical DLBCL cell line. Then, 
we compared the respective effects of different ART deriva-
tives, which identified SM1044 as the most effective one 
(Fig. 1B). Three DLBCL cell lines, SU- DHL- 4, SU- DHL- 10, 
and OCI- LY3 were then used to test the effectiveness of 
SM1044 on cell viability, with the findings that all three 
cell lines were highly sensitive to SM1044 (Fig. 1C).
We then observed that SM1044 treatment increased the 
proportion of cells in the G0/G1 phase of the cell cycle 
while decreasing the number of cells in S phase, suggesting 
that SM1044 could cause a G1 phase arrest (Fig. S1A). 
Apoptosis, tested using the FITC- Annexin V/PI method, 
was also found to be significantly induced by SM1044 
(SU-DHL-4: 0 μmol/L vs. 0.05 μmol/L, P = 0.042; 
0.1 μmol/L, P < 0.001; 0.5 μmol/L, P < 0.001; 1 μmol/L, 
Figure 1. SM1044 induces caspase- dependent apoptosis in DLBCL cell lines. (A) Structural formula of SM1044. (B) SU- DHL- 4 cells were treated with 
the indicated concentrations of SM1044, DHA, ART, ARS, and ARM for 24 h, respectively. Cell viability was measured by CCK- 8 and the percent 
inhibitions were calculated (mean ± SEM, n = 3). (C) SU- DHL- 4, SU- DHL- 10, and OCI- LY3 cells were treated with the indicated concentrations of 
SM1044 for 24 h. The cell viability was measured by CCK- 8 and the percent inhibitions were calculated (mean ± SEM, n = 3). (D) SU- DHL- 4, SU- 
DHL- 10, and OCI- LY3 cells were treated with the indicated concentrations of SM1044 for 24 h. Cell apoptosis was detected by flow cytometry using 
the FITC- Annexin V/PI apoptosis detection kit (mean ± SEM, n = 3). SU- DHL- 4: 0 μmol/L versus 0.05 μmol/L, P = 0.042; 0.1 μmol/L, P < 0.001; 
0.5 μmol/L, P < 0.001; 1 μmol/L, P = 0.0061. SU- DHL- 10: 0 μmol/L versus 0.1 μmol/L, P = 0.023; 0.5 μmol/L, P < 0.001; 1 μmol/L, P < 0.001; 5 μmol/L, 
P < 0.001. OCI- LY3: 0 μmol/L versus 0.05 μmol/L, P = 0.034; 0.1 μmol/L, P < 0.001; 0.5 μmol/L, P < 0.001; 1 μmol/L, P < 0.001. (E) SU- DHL- 4 cells 
were treated with SM1044 for 24 h. Representative electron microscopy photomicrographs are shown. The red arrows point to the apoptosis bodies. 
(F) The expressions of caspase- 8, - 9, - 3, and PARP were detected by western blot in SU- DHL- 4, SU- DHL- 10, and OCI- LY3 cells treated with the 
indicated concentrations of SM1044 for the indicated time courses. (G) Apoptosis was measured in SU- DHL- 4, SU- DHL- 10, and OCI- LY3 cells 
pretreated with caspase inhibitor Z- VAD- FMK for 1 h, and then treated with SM1044 for another 24 h (mean ± SEM, n = 3). SU- DHL- 4: SM1044 
versus control, P < 0.001; SM1044 versus Z- VAD- FMK plus SM1044, P < 0.001. SU- DHL- 10: SM1044 versus control, P < 0.001; SM1044 versus Z- 
VAD- FMK plus SM1044, P < 0.001. OCI- LY3: SM1044 versus control, P < 0.001; SM1044 versus Z- VAD- FMK plus SM1044, P < 0.001. *P < 0.05, 
**P < 0.01, ***P < 0.001.
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P = 0.0061; SU-DHL-10: 0 μmol/L vs. 0.1 μmol/L, P = 0.023; 
0.5 μmol/L, P < 0.001; 1 μmol/L, P < 0.001; 5 μmol/L, 
P < 0.001; OCI-LY3: 0 μmol/L vs. 0.05 μmol/L, P = 0.034; 
0.1 μmol/L, P < 0.001; 0.5 μmol/L, P < 0.001; 1 μmol/L, 
P < 0.001) (Fig. 1D). Likewise, SM1044 also induced a 
loss of mitochondrial membrane potential (MMP) 
(0 μmol/L vs. 0.05 μmol/L, P = 0.0017; 0.1 μmol/L, 
P = 0.0070; 0.5 μmol/L, P < 0.001; 1 μmol/L, P < 0.001) 
(Fig. S1B). Furthermore, the appearance of apoptotic bodies 
was also observed by transmission electron microscopy 
(TEM) (Fig. 1E), as well as the cleavage of apoptosis- 
related proteins caspase- 8, - 9, - 3, and PARP by western 
blot (Fig. 1F). It is of note that, in agreement with a 
previous report [29], we observed that caspase- 8 was rarely 
expressed in SU- DHL- 10 cell line (data not shown). 
Moreover, apoptosis induced by SM1044 was significantly 
reduced by a pretreatment with the pan- caspase inhibitor 
Z- VAD- FMK, demonstrating that the apoptosis triggered 
by SM1044 was caspase- dependent (SU-DHL-4: SM1044 
vs. control, P < 0.001; SM1044 vs. Z- VAD- FMK plus 
Figure 2. SM1044- induced autophagy. (A) SU- DHL- 4 cells were treated with SM1044 for 24 h. Representative electron microscopy photomicrographs 
are shown. The green triangles indicate autophagosomes and the yellow triangles indicate autophagolysosomes. (B) GFP- LC3 plasmids were 
transfected into SU- DHL- 4 cells. Forty- eight hours later, cells were pretreated by CQ for 1 h, followed by a SM1044 treatment for another 24 h. LC3 
puncta are shown by fluorescence microscope. (C) SU- DHL- 4, SU- DHL- 10, and OCI- LY3 cells were treated with the indicated concentrations of 
SM1044 for the indicated time courses. The expression of LC3 was detected by western blot. (D) SU- DHL- 4, SU- DHL- 10, and OCI- LY3 cells were 
pretreated with CQ or Baf A1 for 1 h, followed by a SM1044 treatment for another 24 h. The expression of LC3 was detected by western blot.
Figure 3. SM1044- induced apoptosis is dependent on the generation of autophagy. (A) SU- DHL- 4, SU- DHL- 10, and OCI- LY3 cells were pretreated 
with CQ or Baf A1 for 1 h, followed by SM1044 treatment for another 24 h. The respective expressions of caspase- 8, - 9, - 3, and PARP were detected 
by western blot. (B) Apoptosis was measured by flow cytometry (mean ± SEM, n = 3). SU- DHL- 4: SM1044 versus control, P < 0.001; SM1044 versus 
CQ plus SM1044, P < 0.001; SM1044 versus Baf A1, P < 0.001. SU- DHL- 10: SM1044 versus control, P < 0.001; SM1044 versus CQ plus SM1044, 
P = 0.0077; SM1044 versus Baf A1, P < 0.001. OCI- LY3: SM1044 versus control, P < 0.001; SM1044 versus Baf A1, P = 0.041. (C) SU- DHL- 4 cells 
were stably transfected with scramble or LC3 shRNA, then treated with SM1044 for 24 h. Apoptosis was measured by flow cytometry (mean ± SEM, 
n = 3). Scramble + SM1044 versus sh- LC3 + SM1044, P = 0.0012. (D) The respective expressions of caspase- 8, - 9, - 3, and PARP were detected by 
western blot in the stably transfected cells after SM1044 treatment for 24 h. *P < 0.05, **P < 0.01, ***P < 0.001.
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SM1044, P < 0.001; SU-DHL-10: SM1044 vs. control, 
P < 0.001; SM1044 vs. Z- VAD- FMK plus SM1044, 
P < 0.001; OCI-LY3: SM1044 vs. control, P < 0.001; SM1044 
vs. Z- VAD- FMK plus SM1044, P < 0.001) (Fig. 1G).
SM1044 induces autophagy in DLBCL cell 
lines
While observing apoptotic bodies by TEM, we also detected 
the appearance of typical autophagic compartments in 
SM1044- treated cells in contrast to untreated cells (Fig. 2A). 
Then, in order to investigate the contribution of the 
autophagy- related gene LC3/ATG8 pathway, GFP- LC3 was 
transiently transfected into SU- DHL- 4 cells by electropora-
tion. The punctuate GFP- LC3 fluorescence was induced 
by SM1044, and was further increased after cells were 
pretreated with the autophagy inhibitor CQ and then by 
SM1044 (Fig. 2B). Besides, the levels of LC3- II increased 
in a concentration- and time- dependent manner, and were 
further augmented after the pretreatment by CQ or Baf 
A1 (another inhibitor of autophagy) (Fig. 2C and D). It 
is worth mentioning that, since CQ itself induced a sig-
nificant apoptosis in OCI- LY3 cells, data of CQ group in 
OCI- LY3 cell line are not shown here or below.
Taken together, these findings support the hypothesis 
that SM1044 is a potent inducer of autophagy.
SM1044- induced apoptosis is autophagy 
dependent
As shown above, both apoptosis and autophagy were 
detected in SU- DHL- 4 cells following the addition of 
SM1044. Interestingly, our western blot results suggested 
that autophagy was induced at much lower concentrations 
and at much earlier time course compared to apoptosis 
(Figs. 1F and 2C). In agreement with this observation, 
TEM showed that, although both autophagy compartments 
and apoptotic bodies were induced 24 h after the addition 
of 0.5 μmol/L SM1044, only autophagy compartments were 
found 6 h after the addition of 0.01 μmol/L SM1044 (Fig. 
S2). Strikingly, the cleavage of caspase- 8, - 9, - 3, and PARP 
was reduced, apoptosis was inhibited, and cell viability 
was increased after the pretreatment of cells with CQ or 
Baf A1, indicating that cells were protected from apoptosis 
when autophagy was inhibited (SU-DHL-4: SM1044 vs. 
control, P < 0.001; SM1044 vs. CQ plus SM1044, P < 0.001; 
SM1044 vs. Baf A1, P < 0.001; SU-DHL-10: SM1044 vs. 
control, P < 0.001; SM1044 vs. CQ plus SM1044, 
P = 0.0077; SM1044 vs. Baf A1, P < 0.001; OCI-LY3: 
SM1044 vs. control, P < 0.001; SM1044 vs. Baf A1, 
P = 0.041) (Figs. 3A and B, S3). Therefore, SM1044- induced 
apoptosis appeared to be autophagy dependent. In order 
to further test this hypothesis, the expression of LC3 in 
SU- DHL- 4 cells was stably knocked down after the expres-
sion of a specific anti- LC3 shRNA. As expected, cell apop-
tosis was reduced in the LC3 knockdown cells compared 
to the control cells (Scramble + SM1044 vs. sh- 
LC3 + SM1044, P = 0.0012) (Fig. 3C and D). Collectively, 
these findings demonstrate that apoptosis induced by 
SM1044 is autophagy dependent.
SM1044 treatment induces an autophagy- 
dependent degradation of Survivin
We next studied the molecular mechanism of autophagy- 
dependent apoptosis. As autophagy is also recognized 
Figure 4. SM044 promotes the acetylation of Survivin, enhances the interaction between Survivin and LC3- II, leading to the degradation of Survivin 
and apoptosis. (A) SU- DHL- 4 cells were pretreated with CQ for 1 h, followed by SM1044 treatment for another 24 h. The respective expressions of 
antiapoptosis proteins were detected by western blot. (B) SU- DHL- 4 cells were pretreated with Baf A1 for 1 h, followed by SM1044 treatment for 
another 24 h. The expression of Survivin was detected by western blot (upper panel). Cells with a stable knockdown of LC3 or control cells (scramble 
shRNA) were treated with SM1044 for 24 h. The expression of Survivin was detected by western blot (lower panel). (C) SU- DHL- 4 cells were treated 
with SM1044 for the indicated time courses. The protein and mRNA levels of Survivin were, respectively, detected by western blot (upper panel) and 
real- time PCR (lower panel, mean ± SEM, n = 3). (D) SU- DHL- 4 cells were pretreated with MG132 or CQ for 1 h, followed by a SM1044 treatment 
for another 24 h. The expression of Survivin was detected by western blot. (E) SU- DHL- 4 cells were pretreated with CQ for 1 h, followed by SM1044 
treatment for another 12 h. Survivin was immunoprecipitated with its antibody. Acetylation of Survivin was detected by western blot. (F) SU- DHL- 4 
cells were pretreated with the p300 inhibitor C646 for 1 h, followed by SM1044 treatment for another 24 h. Acetylation of Survivin was detected by 
western blot after Survivin was immunoprecipitated with its antibody (upper panel). The protein and mRNA levels of Survivin were detected by 
western blot (middle panel) and Real- time PCR (lower panel, mean ± SEM, n = 3), respectively. For real- time PCR, C646: 0 versus 5 μmol/L, P = 0.0086; 
10 μmol/L, P < 0.001; 20 μmol/L, P < 0.001. The ratio of Survivin (with/without SM1044) at the protein level in different concentration groups of C646 
was calculated using ImageJ software. (G) SU- DHL- 4 cells were treated with SM1044 for 12 h. Cell lysates were immunoprecipitated using anti- 
Survivin antibody (IP: Survivin) or normal rabbit IgG. The respective levels of Survivin and LC3 were detected by western blot. (H) SU- DHL- 4 cells were 
pretreated with C646 for 1 h, followed by SM1044 treatment for another 12 h. Cell lysates were immunoprecipitated using the anti- Survivin antibody. 
The levels of Survivin and LC3 were detected by western blot. (I) SU- DHL- 4 cells were stably transfected with empty vector, Survivin, or xLIR motif 
mutated Survivin (PLVX, PLVX- S, PLVX- S- M), respectively. The stable transfected cells were treated with SM1044 for 24 h. Apoptosis was measured 
by flow cytometry (mean ± SEM, n = 3). PLVX + SM1044 versus PLVX- S- M + SM1044, P < 0.001. (J) The stable transfected cells were treated with 
SM1044 (SM) for 24 h. The levels of Survivin, caspase- 3 and PARP were detected by western blot. **P < 0.01, ***P < 0.001 compared with the 
control group without C646 treatment. NS, no significance.
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as a protein degradation system, we speculated that 
autophagy might cause apoptosis through degrading one 
or several antiapoptosis proteins. Our hypothesis was 
that these antiapoptosis proteins could be degraded by 
SM1044 treatment while being preserved by the pretreat-
ment of autophagy inhibitors. To search for this/these 
proteins, SU- DHL- 4 cells were divided into four groups: 
(1) control group, treated with solvent for 24 h; (2) 
SM1044 group, treated with 0.5 μmol/L SM1044 for 24 h; 
(3) CQ group, treated with 100 μmol/L CQ for 25 h; 
(4) SM1044 + CQ group, pretreated with 100 μmol/L 
CQ for 1 h, then adding 0.5 μmol/L SM1044 for another 
24 h. Among several candidate antiapoptotic factors, 
Survivin appeared to be the best target for the SM1044- 
induced degradation by autophagy (Fig. 4A). The 
autophagic degradation of Survivin was further confirmed 
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by the pretreatment of cells with Baf A1 and by the 
knockdown of LC3 (sh- LC3) (Fig. 4B). Subsequently, 
we found that Survivin starts decreasing 12 h after the 
addition of SM1044, which is earlier than cell apoptosis 
but later than the induction of autophagy (Fig. 4C). 
Notably, SM1044 decreased the protein level of Survivin, 
but not its mRNA level (Fig. 4C). Meanwhile, we found 
that a treatment by CQ prevented the degradation of 
Survivin, whereas the proteasome inhibitor MG132 did 
not stabilize the protein, suggesting that the degradation 
of Survivin depended on autophagy, rather than on the 
proteasome (Fig. 4D).
Figure 5. SM1044 induces CaMKK2–AMPK–ULK1 pathway- mediated autophagy through promoting de novo synthesis of ceramide. (A) SU- DHL- 4 
cells were treated with SM1044 for the indicated time courses. The active ULK1, AMPK and mTOR were detected by western blot. (B) SU- DHL- 4 cells 
were pretreated with AMPK inhibitor compound C for 1 h, followed by SM1044 treatment for another 24 h. The levels of LC3, Survivin, and p- AMPK 
were detected by western blot. (C) SU- DHL- 4 cells were pretreated with CaMKK2 inhibitor STO- 609 for 1 h, followed by SM1044 treatment for 
another 24 h. The levels of p- AMPK, Survivin, caspase- 8, - 9, - 3, and PARP were detected by western blot. (D) SU- DHL- 4 cells were treated with 
SM1044 for 3 h and the level of ceramide was detected by HPLC- MS/MS. C24: Control versus SM1044, P = 0.011. C26: Control versus SM1044, 
P = 0.023. (E) SU- DHL- 4 cells were pretreated with ceramide inhibitor S1P for 1 h, followed by SM1044 treatment for another 24 h. The levels of p- 
AMPK and Survivin were detected by western blot. (F) SU- DHL- 4 cells were pretreated with ceramide de novo synthesis inhibitor l- cycloserine for 1 h, 
followed by SM1044 treatment for another 24 h. Cell viability was detected by CCK- 8 (upper panel, mean ± SEM, n = 3) and apoptosis was measured 
by flow cytometry (lower panel, mean ± SEM, n = 3). Cell viability: SM1044 versus control, P < 0.001, SM1044 versus l- cycloserine plus SM1044, 
P < 0.001. Percent apoptosis: SM1044 versus control, P < 0.001, SM1044 versus l- cycloserine plus SM1044, P < 0.001. (G) SU- DHL- 4 cells were 
pretreated with l- cycloserine for 1 h, followed by SM1044 treatment for another 24 h. The levels of p- AMPK, LC3, Survivin, caspase- 8, - 9, - 3, and 
PARP were detected by western blot. *P < 0.05, ***P < 0.001.
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SM1044 treatment stimulates Survivin 
acetylation by p300/CBP, which is required 
for its autophagy- dependent degradation
Then, we wanted to know why Survivin was degraded 
by autophagy after the addition of SM1044. It is reported 
that acetylated Survivin is less stable than its deacetylated 
form [30]. Our results showed that the acetylation level 
of Survivin was significantly enhanced by SM1044 and 
was further increased by the pretreatment by CQ (Fig. 4E). 
Acetylation is triggered and regulated by a series of acetyl-
transferases, among which, p300/CBP is one of the most 
important ones. Thus, C646 (a p300/CBP inhibitor) was 
used to inhibit the acetyltransferase activity of p300/CBP. 
As a result, we found that C646 significantly reversed the 
acetylation of Survivin induced by SM1044. More impor-
tantly, although C646 downregulated the expression of 
Survivin both at its mRNA (C646: 0 μmol/L vs. 5 μmol/L, 
P = 0.0086; 10 μmol/L, P < 0.001; 20 μmol/L, P < 0.001) 
and protein levels, the ratio of Survivin (with/without 
SM1044) at the protein level was increased in a 
concentration- dependent manner (63%, 73%, 78%, 98%), 
indicating that C646 was able to inhibit the turnover of 
Survivin (Fig. 4F). Taken together, these findings indicate 
that Survivin is acetylated by p300/CBP and thus degraded 
through autophagy after the SM1044 treatment.
SM1044 induces the interaction of Survivin 
and LC3- II, leading to the degradation of 
Survivin and the induction of apoptosis
To clarify how acetylated Survivin can be degraded by 
autophagy, we analyzed the amino acid sequence of Survivin 
and found an extended LC3- interacting region motif (xLIR 
motif) “EFLKL,” which is highly conserved during evolu-
tion. Hence, we tested the possibility of an interaction 
between LC3- II and Survivin in SU- DHL- 4 cells. Our 
results showed that Survivin slightly binds to LC3- II in 
the absence of SM1044, and that this binding significantly 
increases after the addition of SM1044 (Fig. 4G). 
Interestingly, we also observed that C646 abolishes the 
enhanced interaction between Survivin and LC3- II, sug-
gesting that the interaction between these two proteins 
is dependent on the acetylation of Survivin (Fig. 4H).
In order to further investigate the role of Survivin 
degradation in the induction of apoptosis, PLVX- IRES- 
Puro vector (PLVX), Survivin (PLVX- S), and xLIR motif 
mutated Survivin (PLVX- S- M) were, respectively, stably 
transfected into SU- DHL- 4 cells. While the overexpression 
of Survivin showed weak ability to decrease the SM1044- 
induced apoptosis, the overexpression of PLVX- S- M sig-
nificantly rescued SU- DHL- 4 cells from apoptosis 
(PLVX + SM1044 vs. PLVX- S- M + SM1044, P < 0.001) 
(Fig. 4I). In accordance with these results, cleaved caspase-
 3 and PARP were reduced in the PLVX- S- M overexpres-
sion experimental condition compared to the vector 
condition (Fig. 4J).
SM1044 induces CaMKK2–AMPK–ULK1 
axis- mediated autophagy through 
promoting de novo synthesis of ceramide
To further investigate how autophagy was induced by 
SM1044, we monitored the activation of ULK1, one of 
the most important autophagy initiation factors, along 
with its upstream regulators mTOR and AMPK. ULK1 
and AMPK were activated as early as 3 h after the addi-
tion of SM1044, while mTOR was not (Fig. 5A). Then, 
compound C (an AMPK inhibitor) was used to inhibit 
the activation of AMPK, resulting in a reduced level of 
LC3- II and a rescue of the expression of Survivin (Fig. 5B). 
Collectively, these observations suggested that the activa-
tion of AMPK is the main cause of SM1044- induced 
autophagy and autophagy- dependent degradation of 
Survivin.
AMPK is activated by LKB1 under the condition of 
an elevated AMP/ATP (or ADP/ATP) ratio [31]. We 
observed that LKB1 was persistently activated with or 
without the addition of SM1044 (Fig. S4A). However, we 
found no significant change in the cellular ATP level after 
the addition of SM1044, indicating that AMPK is not 
activated by LKB1 in our model system (Fig. S4B). AMPK 
has also been reported to be activated by Ca2+/calmodulin- 
dependent kinase kinases (CaMKKs), especially CaMKK2, 
which is independent from changes in adenine nucleotides 
[32]. Therefore, we tested the effect of STO- 609, an inhibi-
tor of CaMKK2. As a result, we observed that STO- 609 
reversed the activation of AMPK induced by SM1044 and 
rescued the expression of Survivin. Accordingly, the respec-
tive cleavages of caspase- 8, - 9, - 3, and PARP were also 
reduced by STO- 609 (Fig. 5C). Taken together, these 
results demonstrate that AMPK is activated by CaMKK2 
after the treatment of SM1044.
Tetrahydrocannabinol (THC) is reported to induce the 
synthesis of ceramide, thus mediating autophagy- dependent 
apoptosis through CaMKK2 [33]. It is also reported that 
ART is able to induce the generation of ceramide [34]. 
Thus, we detected ceramide using high- performance liquid 
chromatography–mass spectrometry (HPLC- MS/MS) and 
found increased levels of C24 and C26 ceramide 3 h after 
the addition of SM1044 (C24: control vs. SM1044, 
P = 0.011; C26: control vs. SM1044, P = 0.023). Besides, 
C18, C20, and C22 ceramides also had a tendency to 
increase (P > 0.05) (Fig. 5D). Next, S1P (an inhibitor of 
ceramide) was used to interfere with ceramide signaling 
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showing a diminished activation of AMPK compared to 
the solvent control group after SM1044 treatment (Fig. 5E). 
Interestingly, the expression of Survivin was also rescued 
by S1P (Fig. 5E). Moreover, we observed that l- cycloserine, 
the specific inhibitor of de novo synthesis of ceramide, 
could reverse SM1044- induced cell viability inhibition and 
apoptosis (cell viability: SM1044 vs. control, P < 0.001, 
SM1044 vs. l- cycloserine plus SM1044, P < 0.001; percent 
apoptosis: SM1044 vs. control, P < 0.001, SM1044 vs. 
l- cycloserine plus SM1044, P < 0.001) (Fig. 5F). 
Furthermore, we found that l- cycloserine also inhibited 
the activation of AMPK, the formation of LC3- II, the 
degradation of Survivin, as well as the cleavages of caspase-
 8, - 9, - 3, and PARP (Fig. 5G). Taken together, these results 
demonstrate that SM1044 can induce the de novo synthesis 
of ceramide and thus activate AMPK through CaMKK2.
ARTs degrade Survivin in DLBCL cell lines
Considering that SM1044 is an ART derivative, we further 
assessed the effects of other ARTs on the degradation of 
Survivin in SU- DHL- 4 cells. The results showed that besides 
SM1044, DHA and ARS could also downregulate the 
expression of Survivin (Fig. 6A). We also found that both 
CQ and Baf A1 could reverse the degradation of Survivin 
induced by DHA (Fig. 6B). Interestingly, we also found 
a time- dependent degradation of Survivin by SM1044 in 
both OCI- LY3 and SU- DHL- 10, the other two DLBCL 
cell lines (Fig. 6C).
The in vivo effects of SM1044 on DLBCL
Finally, we tested the effects of SM1044 in vivo. Nude 
mice models of human DLBCL were established by sub-
cutaneously inoculating SU- DHL- 4 cells. Tumor- bearing 
mice were treated with normal saline (n = 11) or SM1044 
(n = 12), respectively, and the body weight and the tumor 
volume of each mouse was measured every other day. 
Although there was no difference in tumor sizes before 
SM1044 treatment, the growth rate was lower in the 
SM1044- treated group compared to the normal saline- 
treated group (Fig. 6D and E). On day 0, the mean body 
weights of normal saline- treated and SM1044- treated groups 
were (19.4 ± 0.5) g and (19.3 ± 0.6) g (P = 0.89), respec-
tively, and the mean tumor volumes were 
(73.6 ± 13.6) mm3 and (77.6 ± 14.2) mm3 (P = 0.84), 
respectively. However, on day 24, the mean body weights 
of normal saline- treated and SM1044- treated group were 
(19.3 ± 0.5) g and (18.9 ± 0.6) g (P = 0.60), respectively, 
while the mean tumor volumes were (1315.2 ± 200.4) mm3 
and (734.3 ± 177.4) mm3 (P = 0.04), respectively.
Discussion
Although nowadays with the R- CHOP regimen more than 
half of DLBCL patients are able to achieve sustained 
remission, the outcome of nonresponders is still dismal. 
Therefore, additional effective and well- tolerated drugs are 
needed. The antitumor activity of ART, a safe and highly 
effective antimalarial drug, has been demonstrated both 
in vitro and in animal models [18, 19]. Better yet, ARS, 
a water- soluble derivative of ART, is proved to be effec-
tive for DLBCL treatment, and has also been reported 
to sensitize B- cell lymphoma to rituximab [20, 21]. To 
further improve the anti- DLBCL effect of ARTs, we syn-
thesized SM1044, a new water- soluble ART maleate, and 
demonstrated that, among several tested ARTs, SM1044 
has the best inhibitory effect on the DLBCL cell line 
SU- DHL- 4. We also observed that SM1044 induces apop-
tosis in DLBCL cell lines. More interestingly, we found 
that the apoptosis induced by SM1044 is dependent on 
autophagy induction.
As a “self- eating” process, autophagy acts as a double- 
edged sword. On the one hand, through degrading and 
recycling cytoplasm and organelles, autophagy generates 
energy and materials to produce new proteins or mem-
branes, allowing cells to adapt to the adverse environ-
ment, thus protecting cells from death. On the other 
hand, autophagy may also promote cell death in several 
situations. (1) In some cases, for instance when apoptosis 
is compromised, autophagy may directly act as an alter-
native cell death pathway, namely type II programmed 
cell death [35]. (2) During autophagy, catalase may also 
be selectively degraded, causing ROS accumulation and 
necrosis cell death [36]. (3) Autophagy can also directly 
induce apoptosis. 1- (1- Benzyl- 5- (4- chlorophenyl)- 1H- 1,
Figure 6. Degradation of Survivin by ARTs and in vivo effect of SM1044. (A) SU- DHL- 4 cells were treated with ART and several ART derivatives (as 
indicated). The expression of Survivin was detected by western blot. (B) SU- DHL- 4 cells were pretreated with CQ or Baf A1 for 1 h, followed by DHA 
treatment for another 24 h. The expression of Survivin was detected by western blot. (C) SU- DHL- 10 and OCI- LY3 cells were treated with SM1044 
for the indicated time courses. The expression of Survivin was detected by western blot. (D) Nude mice with grafted tumors were treated with 
SM1044 (n = 12, 5 mg/kg per day) or vehicle control (n = 11, control) every day. Body weights and tumor volumes were measured every other day 
and plotted on the curve diagram. On day 0, the mean body weights of normal saline- treated and SM1044- treated groups were (19.4 ± 0.5) g and 
(19.3 ± 0.6) g (P = 0.89), respectively, and the mean tumor volumes were (73.6 ± 13.6) mm3 and (77.6 ± 14.2) mm3 (P = 0.84), respectively. However, 
on day 24, the mean body weights of normal saline- treated and SM1044- treated groups were (19.3 ± 0.5) g and (18.9 ± 0.6) g (P = 0.60), respectively, 
while the mean tumor volumes were (1315.2 ± 200.4) mm3 and (734.3 ± 177.4) mm3 (P = 0.04), respectively. *P < 0.05. (E) Representative images 
of control and SM1044- treated tumors.
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2,3- triazol- 4- yl)- 2- (4- bromophenylamino)- 1- (4- chloroph
enyl) ethanol is reported to induce autophagy- dependent 
apoptosis in breast cancer cells both in vitro and in 
vivo [26]. Human immunodeficiency virus type 1 (HIV- 
1) envelope (Env) glycoproteins are proved to be able 
to induce autophagy- dependent apoptosis in HIV- 1 infec-
tion [37]. Similar results are also observed when citreo-
viridin (a mycotoxin and potent inhibitor of 
mitochondrial ATPase) is used in HepG2 cells, YM155 
(a small molecule suppressor of Survivin) in prostate 
cancer cells and cyathin Q (a new cyathane type diter-
pene) in HCT116 cells [24, 25, 27]. However, the mecha-
nism of autophagy- dependent apoptosis has not been 
well elucidated.
In the present study, we demonstrate that SM1044 
induces autophagy- dependent apoptosis in DLBCL cell 
lines. Additionally, we observed that SM1044 degrades 
the antiapoptosis protein Survivin through autophagy. 
Interestingly, YM155 (Survivin inhibitor) can also induce 
autophagy- dependent apoptosis in prostate cancer cells 
[25]. Survivin is a member of the IAPs family and is 
considered as one of the most potent apoptosis inhibitors. 
Of note, Survivin is expressed in a cell cycle- dependent 
manner: it is minimally expressed in G1 phase, its expres-
sion increases in S phase, and reaches a peak in the G2/M 
phase. The knockdown of Survivin induces a G1 phase 
arrest in several different types of tumor cells [38, 39]. 
Accordingly, our results show that a SM1044 treatment 
also induces a measurable increase in the proportion of 
DLBCL cells at the G1 phase of the cell cycle (Fig. S1A).
Survivin is shown to be acetylated by the histone acetyl-
transferase cAMP response element- binding protein- binding 
protein (CBP) or p300/CBP [40]. Acetylation of lysine 129 
in Survivin is responsible for its nuclear localization, while 
deacetylation of lysine 129 promotes its nuclear export. Since 
Survivin is reported to be less stable in the nucleus [41], 
increased acetylation of Survivin may suppress its nuclear 
export and promote its degradation. In agreement with this 
hypothesis, histone deacetylase (HDAC) inhibitor SAHA not 
only induces the acetylation of Survivin and its nuclear trans-
location, but also reduces the stability of Survivin in breast 
cancer cells [30]. Here, we observed that the acetylation of 
Survivin is significantly increased after the addition of SM1044. 
Meanwhile, inhibiting p300/CBP rescued the degradation of 
Survivin. These results further support the hypothesis that 
the acetylation of Survivin accelerates its degradation.
Here we show that Survivin is degraded by SM1044 
through autophagy, whereas the published data on the 
effect of SAHA suggested an acetylation- dependent deg-
radation of Survivin through the proteasome. It is therefore 
possible that the degradation of acetylated Survivin is 
dependent on site- specific acetylation. Indeed, SAHA and 
SM1044 treatment could lead to different site- specific 
acetylations of Survivin, which would result in different 
fates of the acetylated protein.
Next, we showed that acetylated Survivin interacts with 
LC3- II and is degraded by autophagy, leading to the induc-
tion of apoptosis. In agreement with our findings on the 
role of Survivin in inhibiting autophagy and apoptosis, it 
was previously reported that the upregulation of Survivin 
by the C- C motif chemokine ligand 2 (CCL2) inhibited 
autophagic cell death [42]. In that study, the authors also 
found that Survivin could interact with LC3. Interestingly, 
they found that, although the expression of Survivin was 
upregulated by CCL2, the interaction between Survivin and 
LC3 was decreased by CCL2. These results are in line with 
our proposed mechanism which suggests that the interac-
tion between Survivin and LC3 promotes Survivin’s deg-
radation through autophagy. However, the authors did not 
elucidate why and how Survivin interacted with LC3, nor 
did they explore the relationship between the Survivin- LC3 
interaction and the autophagic cell death inhibition.
In addition, we observed that ULK1 activation, one of 
the first steps of autophagy initiation, is induced by SM1044. 
Phosphorylation plays an important role in regulating the 
activity of ULK1. mTOR directly phosphorylates ULK1 at 
the inactivating site (Ser 757) to inhibit autophagy. AMPK 
directly phosphorylates ULK1 at the activating sites (Ser 
317 or Ser 777) to induce autophagy [43]. Moreover, AMPK 
can also inactivate mTOR, thus indirectly activating ULK1 
[44]. In the present work, we observe that SM1044 activates 
ULK1 through the AMPK pathway instead of the mTOR 
pathway. AMPK is mainly regulated by two factors: the 
ratio of AMP/ATP and the intracellular level of Ca2+ [45]. 
When the ratio of AMP/ATP rises, the activity of AMPK 
is enhanced by a LKB1- dependent phosphorylation. Likewise, 
when the intracellular level of Ca2+ increases, CaMKK2 is 
activated, which subsequently leads to the activation of 
AMPK. In this study, we found that SM1044 activates the 
AMPK- ULK1 axis which is mediated by CaMKK2.
It has been reported that THC induces the accumula-
tion of ceramide, which leads to the AMPK- dependent 
autophagy via activating CaMKK2 [33]. Interestingly, under 
this condition, autophagy also promotes apoptosis. 
Moreover, ART has been reported to induce ceramide in 
Plasmodium falciparum parasites, which plays a key role 
in the antimalarial activity of ART [34].
Ceramide has been shown to induce autophagy in sev-
eral different ways: (1) inhibiting Akt, thus inducing 
autophagy through the suppression of the Akt- mTOR 
signaling pathway [46]; (2) activating JNK, which phos-
phorylates Bcl2 and releases Beclin1 from Bcl2 thereby 
inducing autophagy [47]; and (3) suppressing the expres-
sion of nutrient transporter proteins, which results in 
AMPK- mediated autophagy and cell death under nutrient- 
rich conditions [48]. In the present study, we found that 
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the ART derivative SM1044 induces AMPK- dependent 
autophagy through de novo synthesis of ceramide, since 
both the inhibitor of ceramide (S1P) and the inhibitor 
of de novo synthesis of ceramide (l- cycloserine) reversed 
the effects of SM1044 (Fig. 5E–G). Ceramide synthase, 
which locates in the endoplasmic reticulum (ER), is respon-
sible for catalyzing the de novo synthesis of ceramide. 
Interestingly, a fluorescent ART derivative mainly locates 
to the ER [49]. Therefore, whether SM1044, the new 
derivative of ART, induced the de novo synthesis of cera-
mide directly or indirectly through ceramide synthase 
needs to be further investigated.
In conclusion, we synthesized a new water- soluble deriva-
tive of ART, called SM1044, and demonstrated its ability to 
trigger autophagy and an autophagy- dependent apoptosis. 
Furthermore, we unraveled the mechanism underlying the 
SM1044- induced autophagy- dependent apoptosis. Upon 
SM1044 treatment, we observed enhanced acetylation of 
Survivin, which in turn favors its interaction with LC3- II 
and promotes the degradation of Survivin by autophagy. 
Additionally, we also provided evidence that SM1044 also 
activates AMPK, which is a key player in autophagy- dependent 
apoptosis, by inducing de novo synthesis of ceramide.
These properties of SM1044 explain why SM1044 affects 
DLBCL cell survival in vitro and in vivo and argue in 
favor of its use in anti- DLBCL therapeutic approaches.
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Supporting Information
Additional supporting information may be found in the 
online version of this article:
Figure S1. Inhibitory effect of SM1044 on SU- DHL- 4 
cells. (A) SU- DHL- 4 cells were treated with the indicated 
concentrations of SM1044 for 24 h. The proportions of 
cells at each phase of the cell cycle were determined by 
flow cytometry (mean ± SEM, n = 3). (B) SU- DHL- 4 
cells were treated with the indicated concentrations of 
SM1044 for 24 h. Mitochondrial membrane potential 
(MMP) was measured by flow cytometry (mean ± SEM, 
n = 3). **P < 0.01, ***P < 0.001.
Figure S2. Autophagy is induced prior to apoptosis by 
SM1044. SU- DHL- 4 cells were treated with the indicated 
concentrations of SM1044 for 6 or 24 h, respectively. 
Representative electron microscopy photomicrographs are 
shown. The green triangles indicate autophagosome, the 
yellow triangles indicate autolysosome, and the red arrows 
point to the apoptosis bodies.
Figure S3. Autophagy inhibitors reverse the inhibitory 
effect of SM1044 in SU- DHL- 4 cells. SU- DHL- 4 cells were 
pretreated with CQ or Baf A1 for 1 h, followed by SM1044 
treatment for another 24 h. Cell viability was measured 
by CCK- 8 (mean ± SEM, n = 3). ***P < 0.001.
Figure S4. No significant changes were observed in the 
activity of LKB1 or ATP level after the addition of SM1044. 
SU- DHL- 4 cells were treated with SM1044 for the indi-
cated time courses. The expression of p- LKB1 was detected 
by western blot (A) and the level of ATP was detected 
by an enhanced ATP assay kit (mean ± SEM, n = 3) 
(B). NS, no significance.
